Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety, tolerability, and immunogenicity of a Meningococcal B recombinant vaccine in healthy infants, given with or without routine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Meningococcal B Recombinant Vaccine (Meningococcal B recombinant vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2015-03-23